You just read:

Xynomic Pharma Acquires Global Exclusive Rights to Phase 2 Ready mTORC1/2 Inhibitor from Boehringer Ingelheim

News provided by

Xynomic Pharmaceuticals, Inc.

Dec 20, 2018, 10:52 ET